ERAS-4001 for advanced solid tumors with mutations
Part of Cancer clinical trials.
This trial tests a new oral drug called ERAS-4001 for people with advanced solid tumors that have a specific genetic change and are no longer helped by standard treatments. It aims to see if the drug is safe and can shrink tumors.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- Your cancer must have a specific genetic mutation and no longer respond to standard treatments, or you cannot take those treatments.
- You need to be able to swallow pills and have a good performance status (ECOG 0 or 1, meaning you can do daily activities mostly without help).
- Your heart, liver, kidney, and blood cell counts must be within safe limits.
- You cannot have had a RAS inhibitor before, and must not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an experimental oral drug called ERAS-0015 for people with advanced solid tumors that have certain genetic changes (RAS mutations). It may be an option if you have no standard treatments left or cannot take them.
This trial tests new drugs called RAS(ON) inhibitors combined with ivonescimab for people with solid tumors that have a RAS mutation. It aims to see if this combination can shrink tumors or slow their growth.
This trial tests a new drug, HRS-7172, for people with advanced solid tumors that have RAS mutations or amplifications. It aims to see if the drug is safe and effective for these cancers.
This trial tests a new drug, HRS-6093, for people with advanced solid tumors that have a specific genetic change called KRAS G12D. The goal is to see if the drug is safe and effective for those who have not responded to or cannot tolerate other treatments.
This trial tests a new drug (ANS014004) for people with advanced solid tumors that have a specific gene change (MET, ROS1, or NTRK). It aims to see if the drug is safe and can shrink tumors.
This study tests a new drug called ES014 for people with advanced solid tumors that can't be removed or have spread. It's an early trial to see if ES014 is safe and helps fight certain cancers.
Hear when a new Metastatic Solid Tumors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.